Primary Prevention of Cancer-Associated Thrombosis: Current Perspectives

Abstract

Over the past two decades, the incidence of cancer-associated thrombosis (CAT) has increased. It is nowadays a common and often serious complication among patients with cancer. Although medical thromboprophylaxis is recommended for most surgical and nonsurgical cancer patients, it has been infrequently used in ambulatory patients with cancer because of the burden of treatment and concerns about bleeding. However, various risk assessment scores are now available and randomized placebo-controlled trials have established the efficacy of low-molecular-weight heparin or the direct oral Xa inhibitors rivaroxaban and apixaban in ambulatory patients with cancer at high risk of venous thromboembolism (VTE). This review provides an overview of (1) primary thromboprophylaxis in the setting of hospitalized surgical and medical patients, (2) extended thromboprophylaxis after hospital discharge, (3) performance of risk assessment tools for CAT, and (4) primary thromboprophylaxis in ambulatory patients with cancer. The aim is to provide support to physicians in identifying ambulatory patients with cancer at high VTE risk who benefit most from medical thromboprophylaxis according to current recommendations from international guidelines.

Zusammenfassung

In den letzten zwei Jahrzenten wird eine Zunahme der Inzidenz von venösen Thromboembolien (VTE) bei Patienten mit Tumorerkrankung beobachtet. Patienten mit Krebserkrankung weisen neben dem Thromboserisiko ein erhöhtes Risiko für Blutungen auf. Während die medikamentöse Thromboseprophylaxe bei an Krebs erkrankten Patienten nach größeren tumorchirurgischen Eingriffen etabliert ist und bei hospitalisierten Tumorpatienten mit akut internistischen Erkrankungen und Immobilisierung empfohlen wird, stellt die Frage nach primärer Thromboseprophylaxe bei ambulanten Tumorpatienten weiterhin eine klinische Herausforderung dar. Mittlerweile stehen eine Vielzahl an VTE-Risikovorhersagemodellen zur Verfügung, die eine objektive Einschätzung des individuellen VTE-Risikos ermöglichen mit dem Ziel, Patienten mit hohem Risiko zu identifizieren, die von einer medikamentösen Thromboseprophylaxe profitieren. In den letzten Jahren wurden bei Patienten mit hohem VTE-Risiko Studien durchgeführt, die niedermolekulares Heparin bzw. die oralen Xa-Inhibitoren Apixaban und Rivaroxaban gegenüber Placebo verglichen haben.

Dieser Artikel gibt einen Überblick über aktuelle Empfehlungen zur medikamentösen Thromboseprophylaxe nach größeren operativen Eingriffen sowie bei hospitalisierten internistisch kranken Tumorpatienten. Der Fokus des Artikels liegt auf der Primärprophylaxe bei ambulanten Tumorpatienten. Anhand von VTE-Risikovorhersagemodellen sowie den Empfehlungen aus aktuellen Leitlinien wird dargestellt, welche ambulanten Tumorpatienten von einer Thromboseprophylaxe profitieren und wie diese durchgeführt werden kann.

Keywords

cancer - thrombosis - prophylaxis - ambulatory patients - anticoagulants

Schlüsselwörter

Tumorerkrankung - Thrombose - Thromboseprophylaxe - ambulante Krebspatienten - Antikoagulanzien

Authors' Contributions

C.H. and M.V. wrote the manuscript. All authors contributed to the manuscript drafting, reviewed the manuscript, and approved the final version.

Publikationsverlauf

Eingereicht: 19. Juni 2024

Angenommen: 26. Juli 2024

Artikel online veröffentlicht:
10. Oktober 2024

• References

• 1 Mulder FI, Horváth-Puhó E, van Es N. et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood 2021; 137 (14) 1959-1969
• 2 Moik F, Ay C. Venous and arterial thromboembolism in patients with cancer treated with targeted anti-cancer therapies. Thromb Res 2022; 213 (Suppl. 01) S58-S65
• 3 Moik F, Ay C, Pabinger I. Risk prediction for cancer-associated thrombosis in ambulatory patients with cancer: past, present and future. Thromb Res 2020; 191 (Suppl. 01) S3-S11
• 4 Dickmann B, Ahlbrecht J, Ay C. et al. Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study. Haematologica 2013; 98 (08) 1309-1314
• 5 Roy DC, Wang TF, Lun R. et al. Inherited thrombophilia gene mutations and risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. Am J Hematol 2024; 99 (04) 577-585
• 6 Gimbel IA, Mulder FI, Bosch FTM. et al. Pulmonary embolism at autopsy in cancer patients. J Thromb Haemost 2021; 19 (05) 1228-1235
• 7 Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5 (03) 632-634
• 8 Khorana AA, Mackman N, Falanga A. et al. Cancer-associated venous thromboembolism. Nat Rev Dis Primers 2022; 8 (01) 11
• 9 Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343 (25) 1846-1850
• 10 Moik F, Chan WE, Wiedemann S. et al. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. Blood 2021; 137 (12) 1669-1678
• 11 Crobach MJT, Anijs RJS, Brækkan SK. et al. Survival after cancer-related venous thrombosis: the Scandinavian Thrombosis and Cancer Study. Blood Adv 2023; 7 (15) 4072-4079
• 12 Kaptein FHJ, Stals MAM, Kapteijn MY. et al. Incidence and determinants of thrombotic and bleeding complications in patients with glioblastoma. J Thromb Haemost 2022; 20 (07) 1665-1673
• 13 Iyengar V, Patell R, Zwicker J. Challenges in anticoagulation for patients with brain tumors. Best Pract Res Clin Haematol 2022; 35 (01) 101350
• 14 Xiao B, Wang W, Zhang D. Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials. OncoTargets Ther 2018; 11: 5059-5074
• 15 Hussaini P, Larsen TL, Ghanima W, Dahm AEA. Risk factors for bleeding in cancer patients treated with conventional dose followed by low-dose apixaban for venous thromboembolism. Thromb Haemost 2024; 124 (04) 351-362
• 16 Trujillo-Santos J, Nieto JA, Tiberio G. et al; RIETE Registry, Findings from the RIETE Registry. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Thromb Haemost 2008; 100 (03) 435-439
• 17 De Martino RR, Goodney PP, Spangler EL. et al. Variation in thromboembolic complications among patients undergoing commonly performed cancer operations. J Vasc Surg 2012; 55 (04) 1035-1040.e4
• 18 Alikhan R, Cohen AT, Combe S. et al; MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med 2004; 164 (09) 963-968
• 19 Zahir MN, Shaikh Q, Shabbir-Moosajee M, Jabbar AA. Incidence of Venous Thromboembolism in cancer patients treated with cisplatin based chemotherapy - a cohort study. BMC Cancer 2017; 17 (01) 57
• 20 Dharia P, Swartz MD, Bernhardt MB. et al. Clinical and demographic factors contributing to asparaginase-associated toxicities in children with acute lymphoblastic leukemia. Leuk Lymphoma 2022; 63 (12) 2948-2954
• 21 White C, Noble SIR, Watson M. et al. Prevalence, symptom burden, and natural history of deep vein thrombosis in people with advanced cancer in specialist palliative care units (HIDDen): a prospective longitudinal observational study. Lancet Haematol 2019; 6 (02) e79-e88
• 22 Heit JA, Crusan DJ, Ashrani AA, Petterson TM, Bailey KR. Effect of a near-universal hospitalization-based prophylaxis regimen on annual number of venous thromboembolism events in the US. Blood 2017; 130 (02) 109-114
• 23 Gangireddy C, Rectenwald JR, Upchurch GR. et al. Risk factors and clinical impact of postoperative symptomatic venous thromboembolism. J Vasc Surg 2007; 45 (02) 335-341 , discussion 341–342
• 24 Guo Q, Huang B, Zhao J. et al. Perioperative pharmacological thromboprophylaxis in patients with cancer: a systematic review and meta-analysis. Ann Surg 2017; 265 (06) 1087-1093
• 25 Bergqvist D, Agnelli G, Cohen AT. et al; ENOXACAN II Investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002; 346 (13) 975-980
• 26 Kakkar VV, Balibrea JL, Martínez-González J, Prandoni P. CANBESURE Study Group. Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study. J Thromb Haemost 2010; 8 (06) 1223-1229
• 27 Falanga A, Ay C, Di Nisio M. et al; ESMO Guidelines Committee. Electronic address: [e-mail]. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncol 2023; 34 (05) 452-467
• 28 Key NS, Khorana AA, Kuderer NM. et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update. J Clin Oncol 2023; 41 (16) 3063-3071
• 29 Becattini C, Pace U, Pirozzi F. et al. Rivaroxaban vs placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer. Blood 2022; 140 (08) 900-908
• 30 Guntupalli SR, Brennecke A, Behbakht K. et al. Safety and efficacy of apixaban vs enoxaparin for preventing postoperative venous thromboembolism in women undergoing surgery for gynecologic malignant neoplasm: a randomized clinical trial. JAMA Netw Open 2020; 3 (06) e207410
• 31 Turpie AG. Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. Am J Cardiol 2000; 86 (12B): 48M-52M
• 32 Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ. PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110 (07) 874-879
• 33 Cohen AT, Davidson BL, Gallus AS. et al; ARTEMIS Investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006; 332 (7537) 325-329
• 34 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF): S3-Leitlinie Diagnostik, Therapie und Nachsorge der Keimzelltumoren des Hodens. Langversion 1.1. 2020 . Accessed July 31, 2024 at: www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Hodentumore
• 35 EAU Guidelines. Presented at the EAU Annual Congress Paris. 2024 . ISBN: 978-94-92671-23-3
• 36 Zwicker JI, Wang TF, DeAngelo DJ. et al. The prevention and management of asparaginase-related venous thromboembolism in adults: guidance from the SSC on Hemostasis and Malignancy of the ISTH. J Thromb Haemost 2020; 18 (02) 278-284
• 37 Osataphan S, Patell R, Chiasakul T, Khorana AA, Zwicker JI. Extended thromboprophylaxis for medically ill patients with cancer: a systemic review and meta-analysis. Blood Adv 2021; 5 (08) 2055-2062
• 38 Cohen AT, Harrington RA, Goldhaber SZ. et al; APEX Investigators. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med 2016; 375 (06) 534-544
• 39 Cohen AT, Spiro TE, Büller HR. et al; MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 2013; 368 (06) 513-523
• 40 Spyropoulos AC, Barnathan ES, Raskob GE. MARINER Investigators. Thromboprophylaxis after hospitalization for medical illness. N Engl J Med 2018; 379 (23) 2280
• 41 Hull RD, Schellong SM, Tapson VF. et al; EXCLAIM (Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients With Prolonged Immobilization) study. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med 2010; 153 (01) 8-18
• 42 Khorana AA, Dalal M, Tangirala K. et al. Higher incidence of venous thromboembolism in the outpatient versus the inpatient setting among US cancer patients. Blood 2011; 118: 309-310
• 43 Accessed July 31, 2024 at: https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebsgeschehen/Versorgung/Versorgung_node.html . In
• 44 Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111 (10) 4902-4907
• 45 Mulder FI, Candeloro M, Kamphuisen PW. et al; CAT-Prediction Collaborators. The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis. Haematologica 2019; 104 (06) 1277-1287
• 46 Khorana AA, Soff GA, Kakkar AK. et al; CASSINI Investigators. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med 2019; 380 (08) 720-728
• 47 Carrier M, Abou-Nassar K, Mallick R. et al; AVERT Investigators. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med 2019; 380 (08) 711-719
• 48 Kirschner M, do Ó Hartmann N, Parmentier S. et al. Primary thromboprophylaxis in patients with malignancies: daily practice recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO), the Society of Thrombosis and Hemostasis Research (GTH), and the Austrian Society of Hematology and Oncology (ÖGHO). Cancers (Basel) 2021; 13 (12) 2905
• 49 Farge D, Frere C, Connors JM. et al; International Initiative on Thrombosis and Cancer (ITAC) Advisory Panel. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol 2022; 23 (07) e334-e347
• 50 Li A, La J, May SB. et al. Derivation and validation of a clinical risk assessment model for cancer-associated thrombosis in two unique US health care systems. J Clin Oncol 2023; 41 (16) 2926-2938
• 51 Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med 2012; 7 (03) 291-292
• 52 Pelzer U, Opitz B, Deutschinoff G. et al. Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. J Clin Oncol 2015; 33 (18) 2028-2034
• 53 Gerotziafas GT, Taher A, Abdel-Razeq H. et al; COMPASS–CAT Working Group. A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS-Cancer-Associated Thrombosis Study. Oncologist 2017; 22 (10) 1222-1231
• 54 Cella CA, Di Minno G, Carlomagno C. et al. Preventing venous thromboembolism in ambulatory cancer patients: the ONKOTEV Study. Oncologist 2017; 22 (05) 601-608
• 55 Pabinger I, van Es N, Heinze G. et al. A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. Lancet Haematol 2018; 5 (07) e289-e298
• 56 Kumar V, Shaw JR, Key NS. et al. D-dimer enhances risk-targeted thromboprophylaxis in ambulatory patients with cancer. Oncologist 2020; 25 (12) 1075-1083
• 57 Verzeroli C, Giaccherini C, Russo L. et al; HYPERCAN Investigators. Utility of the Khorana and the new-Vienna CATS prediction scores in cancer patients of the HYPERCAN cohort. J Thromb Haemost 2023; 21 (07) 1869-1881
• 58 Agnelli G, Gussoni G, Bianchini C. et al; PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009; 10 (10) 943-949
• 59 Agnelli G, George DJ, Kakkar AK. et al; SAVE-ONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012; 366 (07) 601-609
• 60 Muñoz A, Ay C, Grilz E. et al. A clinical-genetic risk score for predicting cancer-associated venous thromboembolism: a development and validation study involving two independent prospective cohorts. J Clin Oncol 2023; 41 (16) 2911-2925
• 61 Rutjes AW, Porreca E, Candeloro M, Valeriani E, Di Nisio M. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev 2020; 12 (12) CD008500
• 62 Khorana AA, Soff GA, Kakkar AK. et al. Rivaroxaban thromboprophylaxis in high risk ambulatory cancer patients receiving systemic therapy: results of a randomized clinical trial (CASSINI). Blood 2018; 132
• 63 Li A, Carlson JJ, Kuderer NM. et al. Analysis and cost-effectiveness analysis of low-dose direct oral anticoagulant for the prevention of cancer associated thrombosis. Blood 2019; 134
• 64 Laderman L, Sreekrishnanilayam K, Pandey RK. et al. Venous thromboembolism in metastatic pancreatic cancer. Eur J Haematol 2023; 110 (06) 706-714
• 65 Maraveyas A, Waters J, Roy R. et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer 2012; 48 (09) 1283-1292
• 66 Vadhan-Raj S, McNamara MG, Venerito M. et al. Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: results from a pre-specified subgroup analysis of the randomized CASSINI study. Cancer Med 2020; 9 (17) 6196-6204
• 67 Frere C, Crichi B, Bournet B. et al. Primary thromboprophylaxis in ambulatory pancreatic cancer patients receiving chemotherapy: a systematic review and meta-analysis of randomized controlled trials. Cancers (Basel) 2020; 12 (08) 2028
• 68 Khorana AA, Palaia J, Rosenblatt L. et al. Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer. J Immunother Cancer 2023; 11 (01) e006072
• 69 Abufarhaneh M, Pandya RK, Alkhaja A, Iansavichene A, Welch S, Lazo-Langner A. Association between genetic mutations and risk of venous thromboembolism in patients with solid tumor malignancies: a systematic review and meta-analysis. Thromb Res 2022; 213: 47-56
• 70 Moik F, Riedl JM, Ay C. VTE with amivantamab plus chemotherapy in NSCLC. N Engl J Med 2024; 390 (06) 578-579
• 71 Alexander M, Harris S, Underhill C. et al. Risk-directed ambulatory thromboprophylaxis in lung and gastrointestinal cancers: the TARGET-TP Randomized Clinical Trial. JAMA Oncol 2023; 9 (11) 1536-1545
• 72 Mones JV, Streiff MB, Khorana AA. et al. Rivaroxaban thromboprophylaxis for gastric/gastroesophageal junction tumors versus other tumors: a post hoc analysis of the randomized CASSINI trial. Res Pract Thromb Haemost 2021; 5 (05) e12549
• 73 Ladha D, Mallick R, Wang TF, Caiano L, Wells PS, Carrier M. Efficacy and safety of apixaban for primary prevention in gastrointestinal cancers: a post-hoc analysis of the AVERT trial. Thromb Res 2021; 202: 151-154
• 74 Oriol A, Abril L, Ibarra G. First-line treatment of multiple myeloma in both transplant and non-transplant candidates. Expert Rev Anticancer Ther 2023; 23 (07) 685-698
• 75 Charalampous C, Goel U, Kapoor P. et al. Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survival. Am J Hematol 2023; 98 (03) 413-420
• 76 Li A, Wu Q, Luo S. et al. Derivation and validation of a risk assessment model for immunomodulatory drug-associated thrombosis among patients with multiple myeloma. J Natl Compr Canc Netw 2019; 17 (07) 840-847
• 77 Sanfilippo KM, Luo S, Wang TF. et al. Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. Am J Hematol 2019; 94 (11) 1176-1184
• 78 NCCN. Accessed July 31, 2024 at: https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf
• 79 De Stefano V, Larocca A, Carpenedo M. et al. Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel. Haematologica 2022; 107 (11) 2536-2547
• 80 Potere N, Mahé I, Angchaisuksiri P. et al; World Thrombosis Day Steering Committee and Collaborators. Unmet needs and barriers in venous thromboembolism education and awareness among people living with cancer: a global survey. J Thromb Haemost 2024; 22 (07) 1973-1983
• 81 Advancing blood clot awareness. Accessed July 31, 2024 at: https://www.stoptheclot.org/learn_more/awareness/prophylaxis.htm
• 82 Martin KA, Cameron KA, Lyleroehr MJ, Linder JA, O'Brien M, Hirschhorn LR. Venous thromboembolism prevention in cancer care: implementation strategies to address underuse. Res Pract Thromb Haemost 2023; 7 (07) 102173
• 83 Verso M, Muñoz A, Connors JM. Ambulatory cancer patients: who should definitely receive antithrombotic prophylaxis and who should never receive. Intern Emerg Med 2023; 18 (06) 1619-1634
• 84 de Winter MA, Dorresteijn JAN, Ageno W. et al. Estimating bleeding risk in patients with cancer-associated thrombosis: evaluation of existing risk scores and development of a new risk score. Thromb Haemost 2022; 122 (05) 818-829
• 85 Cohen AT, Wallenhorst C, Choudhuri S, Nassar A, Pollock KG, Martinez C. A Novel risk prediction score for clinically significant bleeding in patients anticoagulated for venous thromboembolism with active cancer. Thromb Haemost 2024; 124 (04) 324-336
• 86 Pandey A, Verma R, Eikelboom J, Verma S. Factor XI inhibitors: what should clinicians know. Curr Opin Cardiol 2023; 38 (02) 88-93
• 87 Gailani D, Gruber A. Targeting factor XI and factor XIa to prevent thrombosis. Blood 2024; 143 (15) 1465-1475
• 88 Wang TF, Zwicker JI, Ay C. et al. The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH. J Thromb Haemost 2019; 17: 1772-1778